Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterizing the Preclinical Stages of Alzheimer's Disease and the Prospect of Presymptomatic Intervention

27 Dec 2012

Abstract excerpt

Studies of asymptomatic carriers of genes that are known to predispose to Alzheimer's disease (AD) have facilitated the characterization of preclinical AD. The most prevalent genetic risk factor is the ε4 allele of apolipoprotein E (APOE). Neuropathological studies of young deceased ε4 carriers have shown modest but abnormal amounts of neocortical amyloid and medial temporal neurofibrillary tangles that is also...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Dementia and Cognitive Impairment Research
Share to Ginkgo biloba and Cashew Applications

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22695623
DOI: 10.3233/jad-2012-129026

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 10 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterizing the Preclinical Stages of Alzheimer's Disease and the Prospect of Presymptomatic InterventionPMID 22695623Read ↗

Apolipoprotein E: implications for AD neurobiology, epidemiology and risk assessment.Semantic proximity Read ↗

Preclinical sporadic Alzheimer's disease: target for personalized diagnosis and preventive intervention.Semantic proximity Read ↗

Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study.Semantic proximity Read ↗

Protective genes and pathways in Alzheimer's disease: moving towards precision interventions.Semantic proximity Read ↗

The role of APOE4 in Alzheimer’s disease: strategies for future therapeutic interventionsSemantic proximity Read ↗

Molecular Approaches to the Treatment, Prophylaxis, and Diagnosis of Alzheimer’s Disease: Clinical Molecular and Genetic Studies on Alzheimer’s DiseaseSemantic proximity Read ↗

Preclinical Alzheimer disease-the challenges ahead.Semantic proximity Read ↗

The multifaceted roles of apolipoprotein E4 in Alzheimer’s disease pathology and potential therapeutic strategiesSemantic proximity Read ↗

Effects of APOE ε4 and amyloid pathology on longitudinal tau biomarkers, neurodegeneration, and cognitive decline in mild cognitive impairment.Semantic proximity Read ↗

Age‐dependent effects of <i>APOE</i> ε4 in preclinical Alzheimer's diseaseSemantic proximity Read ↗

Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.Semantic proximity Read ↗

More than just risk for Alzheimer's disease: APOE ε4's impact on the aging brain.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.